Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bear Stearns Healthcare Conference, In Brief

Executive Summary

Abbott D2E7 advisory committee?: Abbott has "not heard anything at all" about a possible early December FDA advisory committee meeting for its anti-TNF monoclonal antibody D2E7 (adalimumab), CFO Thomas Freyman told Bear Stearns healthcare conference in New York City. Abbott does not believe "having a panel or not having a panel is going to impact our timing at all in terms of product launch." In a separate Bear Stearns presentation, Enbrel marketer Amgen Investor Relations Director Anna McDermott-Vitak said she "would be surprised" if D2E7 was not the subject of an advisory committee meeting. Abbott submitted a BLA for D2E7 in rheumatoid arthritis April 2; the company expects to launch adalimumab in the first half of 2003...
Advertisement

Related Content

Tricor noninfringement ruling upheld
Tricor noninfringement ruling upheld
Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules
Philadelphia Rx Fraud Investigations Have New Chief; Are SEC Cases Next?
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
Novartis/Titan Iloperidone Deal In Doubt In Light Of QTc Prolongation Data
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations
Advertisement
UsernamePublicRestriction

Register

PS040531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel